- Professor Richard Schilsky, University of Chicago Medical Centre, USA
- Professor Paul Glasziou, Bond University, Australia
- Professor Nick Barker, Institute of Medical Biology, Singapore
- Professor John Mattick, Garvan Institute for Medical Research
- Professor Sanchia Aranda, Cancer Institute NSW
- Professor Sean Grimmond, University of Queensland
- Associate Professor Penny Schofield, Peter MacCallum Cancer Centre
- Professor Suzanne Chambers, Cancer Council Queensland
- Professor Jan Ussher, University of Western Sydney
- Professor John Rasko, University of Sydney
- Professor Paul Keall, University of Sydney
- Professor Jane Young, University of Sydney
- Associate Professor Erik Thompson, University of Melbourne
- Professor Kum Kum Khanna, Queensland Institute of Medical Research
- Professor Alpha Yap, University of Queensland
- Associate Professor Jennifer Byrne, University of Sydney
- Dr Megan Chircop, University of Sydney
- Professor Pablo Moscato, University of Newcastle
Dr. Schilsky earned his M.D. at the University of Chicago Pritzker School of Medicine in 1975. Following a residency in Internal Medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in Medical Oncology and Clinical Pharmacology at the National Cancer Institute from 1977 to 1981. He then served as Assistant Professor of Medicine at the University of Missouri-Columbia School of Medicine from 1981-1984 when he returned to the University of Chicago where he is presently Professor of Medicine (tenured) and Chief of the Section of Hematology-Oncology in the Department of Medicine. Dr. Schilsky previously served as Director of the University of Chicago Cancer Research Center (1991-99) and as Associate Dean for Clinical Research (1999-2007). From 1995-2010, Dr. Schilsky also served as Chairman of the Cancer and Leukemia Group B, an NCI-sponsored national cancer clinical trials group.
An international expert in gastrointestinal malignancies and cancer pharmacology, he has served on a number of peer review and advisory committees for the NCI including the NCI Board of Scientific Advisors and as a member of the Clinical and Translational Research Advisory Committee. Dr. Schilsky has served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as ASCO President 2008-2009.
Paul Glasziou FRACGP, PhD is Professor of Evidence-Based Medicine at Bond University and a part-time General Practitioner. He was the Director of the Centre for Evidence-Based Medicine in Oxford from 2003-2010. His key interests include identifying and removing the barriers to using high quality research in everyday clinical practice.
Professor Glasziou has authored over 160 peer-reviewed journal articles – half of these since 2004. The articles have a total of over 10,000 citations. His h-index is currently 42, that is, 42 articles have been cited at least 42 times; 18 of these publications having been cited over 100 times. These research articles have appeared in key general medicine journals such as the Lancet (7), NEJM (3), JAMA (4), Annals of Internal Medicine (3), BMJ (16), and the MJA (8), as well as a variety of specialist medical and methodological journals.
He is the author of six books related to evidence based practice: Systematic Reviews in Health Care, Decision Making in Health Care and Medicine: integrating evidence and values, An Evidence-Based Medicine Workbook, Clinical Thinking: Evidence, Communication and Decision-making, Evidence-Based Medicine: How to Practice and Teach EBM, and Evidence-Based Medical Monitoring: Principles and Practice. He is the recipient of an NHRMC Australia Fellowship which he commenced at Bond University in July, 2010.
Nick obtained his PhD from Reading University, UK in 1996. He joined the group of Professor Hans Clevers in Utrecht to investigate the role of the Wnt signaling pathway in intestinal development and cancer. In 2001, he joined a Biotech company co-founded by Hans Clevers (Semaia Pharmaceuticals), where he developed small molecule inhibitors of the Tcf/ß-catenin protein complex as candidate colon cancer therapeutics. In 2006, he rejoined Hans Clevers' group where he identified the Wnt target gene Lgr5 as a unique marker of adult stem cell populations in various organs, including the intestine, skin and stomach. This work led to the discovery that the intestinal Lgr5 stem cells are the cell-of-origin of colon cancer and revealed Lgr5 as a candidate marker of cancer stem cell populations.
In 2010, Nick joined the IMB as Principal Investigator, where he will continue to focus on the role of Lgr5 adult stem cells in epithelial renewal and cancer in organs including stomach and ovary. Nick also holds a visiting professorship at the Center for Regenerative Medicine (CRM) at Edinburgh University and is an associate principal investigator with EuroSyStem.